Lucidi Bruno, a director at Atea Pharmaceuticals, Inc., has reported multiple stock transactions involving the company's common shares. These transactions, filed on November 19, 2026, are significant as they showcase Bruno's active management of his ownership in the pharmaceutical company.
Atea Pharmaceuticals, based in Boston, Massachusetts, operates in the pharmaceutical preparations sector. The company is listed under the SIC code 2834. Recent filings indicate Bruno's ongoing involvement with the company, which is crucial in the competitive pharmaceutical landscape.
The filing details several transactions that occurred on November 17 and November 19, 2026. Bruno acquired 21,628 shares at a price of $1.24 each and sold 6,741 shares at prices ranging from $4.00 to $4.10. Additionally, Bruno acquired 53,372 shares at $1.24 and sold 22,619 shares at prices between $3.91 and $3.97. Following these transactions, Bruno's total ownership in Atea Pharmaceuticals stands at 187,990 shares.
These stock transactions may affect various stakeholders, including other shareholders and potential investors in Atea Pharmaceuticals. The reported activities reflect a strategic approach to share management, which could influence market perceptions of the company's stock.
The filing does not say what happens next, leaving the future direction of Bruno's involvement with Atea Pharmaceuticals open to speculation.
Bruno's transactions included the exercise of stock options, with a significant number of shares acquired at an exercise price of $1.24. Specifically, on November 17, he exercised options for 21,628 shares and later on November 19, he exercised options for an additional 53,372 shares. Following these exercises, his total ownership in Atea Pharmaceuticals increased substantially.
The filing notes that all sale transactions were executed to pay the exercise price of the options and for Bruno's tax planning purposes. This strategic decision highlights the importance of managing stock options effectively, particularly in the context of tax implications.
Additionally, the filing indicates that Bruno's total shares owned following the transactions amounted to 187,990 shares. This figure reflects his ongoing commitment to Atea Pharmaceuticals, as he continues to hold a significant stake in the company.
The filing does not provide insights into Bruno's future plans regarding his shares or any potential impact on Atea Pharmaceuticals' strategic direction.
Read Next
Grove Collaborative director Jason Karp increases stock holdings
Suncrete, Inc. Director Andrew Heyer Acquires 25,000 Shares
Tackett Ross Justyn Discloses Share Ownership in Zscaler
Manchester Management PR, LLC Increases Stake in Modular Medical
CervoMed CEO John Alam Acquires Over 99,000 Shares
Filippo Passerini Sells Shares Following Integer Merger






